Prestige Consumer Healthcare (PBH) News Today

Prestige Consumer Healthcare Inc. (PBH) shares have been under pressure after mixed Q1 results and guidance, though strategic moves such as the Pillar5 Pharma acquisition and improving Clear Eyes supply are providing potential upside.

• Positive Sentiment: Agreement to acquire Pillar5 Pharma, expanding its eye‐care portfolio and expected to drive future revenue growth. Prestige Consumer Healthcare Acquires Pillar5 Pharma for Expansion
• Positive Sentiment: Clear Eyes supply recovery anticipated to normalize sales of a key product line. Prestige Consumer Healthcare outlines $1.1B–$1.115B FY26 revenue target amid Pillar5 acquisition and Clear Eyes supply recovery
• Neutral Sentiment: Fiscal 2026 revenue guidance of $1.10 billion–$1.115 billion is roughly in line with consensus expectations. Prestige Consumer Healthcare (NYSE:PBH) Issues FY 2026 Earnings Guidance
• Neutral Sentiment: Management hosted a detailed Q1 earnings call and presentation, outlining strategy and outlook. Q1 2026 Earnings Call Transcript & Q1 2026 Earnings Call Presentation
• Negative Sentiment: Q1 EPS of $0.95 and revenue of $249.5 million missed Street forecasts ($1.01 EPS; $260.7 million), with revenue down 6.6% year-over-year. Prestige Consumer Healthcare (PBH) Misses Q1 Earnings and Revenue Estimates
• Negative Sentiment: FY 2026 EPS guidance of $4.50–$4.58 falls short of the consensus $4.77, signaling potential margin pressure. Prestige Consumer Healthcare (PBH) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates